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Ting C ZhaoAbstract
Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family implicated in the control of
appetite and satiety. GLP-1 has insulinotropic, insulinomimetic, and glucagonostatic effects, thereby exerting
multiple complementary actions to lower blood glucose in subjects with type 2 diabetes mellitus. A major
advantage over conventional insulin is the fact that the insulinotropic actions of GLP-1 are dependent upon
ambient glucose concentration, mitigating the risks of hypoglycemia. Recently, the crucial role of GLP-1 in
cardiovascular disease has been suggested in both preclinical and clinical studies. The experimental data indicate
GLP-1 and its analogs to have direct effects on the cardiovascular system, in addition to their classic
glucoregulatory actions. Clinically, beneficial effects of GLP-1 have also been demonstrated in patients with
myocardial ischemia and heart failure. GLP-1 has recently been demonstrated to be a more effective alternative in
treating myocardial injury. This paper provides a review on the current evidence supporting the use of GLP-1 in
experimental animal models and human trials with the ischemic and non-ischemic heart and discusses their
molecular mechanisms and potential as a new therapeutic approach.
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Myocardial infarction contributes significantly to deaths
related to coronary artery disease [1]. Diabetes mellitus
threatens to become a global health crisis; treatment of
diabetes and its implications constitutes a major health
care expenditure. A significant proportion of diabetic pa-
tients are known to develop diabetic cardiomyopathy,
with a high incidence of congestive heart failure. The
continuous requirement for high-energy phosphates to
perform mechanical work burdens the heart as meta-
bolic requirements not shared by other organ system.
Accordingly, substrate availability, oxidative phosphoryl-
ation, and high-energy phosphate transfer are critical to
cardiac performance. While the heart is capable of utiliz-
ing a variety of available substrates to generate adenosine
triphosphate, this metabolic flexibility is compromisedCorrespondence: tzhao@bu.edu
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reproduction in any medium, provided the orunder circumstances in which the heart is stressed, par-
ticularly by myocardial ischemia.
Diabetes causes suppressed glucose oxidation leading
to inefficient energy production, enhanced fatty acid me-
tabolism, and increased susceptibility to myocardial ische-
mia and reperfusion injury. In the ischemic myocardium,
an increase in glucose uptake and subsequent ATP gener-
ated through glycolysis helps to sustain myocardial electric
and mechanical performance, maintains cellular ultra-
structure, promotes myocardial recovery. Accordingly,
mechanism of enhancing myocardial energetic efficiency
by stimulating glucose availability and utilization has
led to the vigorous pursuit of therapeutic approaches
designed to augment glucose uptake and oxidation.
Although many therapeutic agents such as β-blockers and
angiotensin-converting enzyme inhibitors are currently
used to control cardiovascular diseases (CVD), there re-
mains a substantially high incidence of CVD among dia-
betic patients, necessitating alternative strategies of
targeted management [2]. One such area of interest is the
ability to modulate myocardial glucose uptake and itsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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infarction are insulin-resistant states that are associated
with a significant risk for either concurrently having or
subsequently developing newly-onset diabetes [3]. Insulin
resistance is implicated in several potential adverse meta-
bolic changes, including disturbances in insulin and glu-
cose metabolism, which can affect energy supply and
blood flow [4]. The injured myocardium develops an
evolving dependence on glucose as its preferred metabolic
substrate while development of myocardial insulin resist-
ance is associated with the progression of heart failure and
increased incidence as well as severity of the damaged
hearts.
Insulin, glucose and potassium (GIK) are touted as
useful metabolic adjuvant, associated with improvement
of cardiac function in acute myocardial function, but the
general acceptance of this therapeutic approach is lim-
ited by requirements for concomitant infusion of glucose
and concerns regarding hypoglycemia. Glucagon-like
peptide-1 (GLP-1) is a naturally occurring incretin that
is implicated in the control of appetite and satiety. GLP-
1 has been studied extensively in type 2 diabetes as a
novel insulinotropic peptide whose actions are predi-
cated upon the ambient glucose concentration. The ex-
perimental studies and clinical data demonstrated that
utilizing GLP-1 as a treatment in patients with heart fail-
ure improved cardiac function. We and others further
have shown that GLP-1 protected the heart against is-
chemic injury. In this brief review, we will summarize re-
cent progress about the promising role of GLP-1 in
myocardial protection and signaling pathway.
GLP-1 and its biological role
Glucagon-like peptide-1 (GLP-1) is a member of the
pro-glucagon incretin family implicated in the control of
appetite and satiety [5]. GLP-1 acts through GLP-1 re-
ceptor (GLP-1R), a 463 amino-acid member of the G
protein-coupled receptor (GPCR) superfamily [6]. Bio-
active GLP-1 exists in two equipotent molecular forms:
GLP-17–37 and GLP-17–36 amide. GLP-1 is rapidly cleaved
by DP IV, which results in the generation of largely in-
active molecular GLP-19-36 amide and GLP-17-37 forms.
The majority of GLP-1 leaving the intestinal venous cir-
culation has already been cleaved by DP IV expressed
in capillary surrounding gut L cells, which provides an
estimated half-life of 1–2 minutes for intact GLP-1
in vivo [7]. The GLP-1 receptor is widely distributed in
tissues, including brain, pancreas, intestine, lung, stom-
ach, and kidney. The effects of GLP-1 appear to be both
insulinotropic and insulinomimetic, depending on the
ambient glucose concentration. GLP-1 is studied exten-
sively in type 2 diabetes as a novel insulinotropic pep-
tide whose actions are predicated upon the ambient
glucose concentration. The actions of GLP-1 tostimulate pancreatic insulin release are attenuated at a
glucose concentration less than 4 mmolar. In addition,
GLP-1 also exerts actions independent of insulin secre-
tion, such as inhibiting glucagon secretion, gastric
emptying, and gastric acid secretion while reducing
food intake after both intracerebroventricular and per-
ipheral administration [8]. There is accumulated evi-
dence showing that administration of GLP-1 agonists
promotes differentiation of functional β cells both
in vitro and in vivo [9,10]. Furthermore, administration
of extendin-4 in the neonatal period to rats following
induction of experimental intrauterine growth retard-
ation is associated with a reduced incidence of diabetes
due to increased β-cell mass cell proliferation [11].
Mechanisms of GLP-1 in the regulation of β-cell mass
remain unclear, but may involve MAP kinase, PKCζ,
and phosphatidylinositol-3 kinase.
In addition, evidence suggests that GLP-1 acting
outside of the pancreas is also important for regula-
tion of glucose metabolism. GLP-1 also has been
shown to stimulate glucose disposal via an insulin-
independent mechanism(s) [12]. Myocardial recep-
tors for GLP-1 are identified in rodents and human
myocardium [13,14]. Although receptors for GLP-1
are found in a variety of tissues including the heart,
current evidence exists mainly to support the role
of GLP as a modulator of pancreatic hormone re-
lease [15]. GLP-1 has been administered as a con-
tinuous infusion in type 2 diabetics with impressive
insulin-sensitizing effects, reduced insulin resistance
in skeletal muscle and adipose tissue, and improve-
ments in insulin-mediated glucose uptake.
Insulin resistance in myocardium
Insulin resistance is commonly defined as a decreased
response of glucose uptake to the stimulatory effect of
insulin [16]. Glucose is an especially important sub-
strate for the heart [17], and influences both normal
cardiac function and the response of the heart to ische-
mia that promotes glucose uptake and decreases the
utilization of free fatty acids by the human heart [18]. A
decrease in glycolysis has been shown in various animal
models of heart failure, and heart failure is linked with
insulin resistance. On the other hand, patients with
chronic heart failure due to coronary artery disease are
more likely to have abnormalities in glucose metabolism
than are patients with congestive heart failure (CHF) due
to idiopathic dilated cardiomyopathy [19]. It has been
demonstrated that in patients with myocardial infarction,
metabolic syndrome and diabetes were highly prevalent
and associated with higher risks of deaths and major
cardiovascular events [20]. In addition, euglycaemic
hyperinsulinaemic clamp techniques reveal that insulin-
stimulated glucose uptakes was 20% lower in congestive
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further extended by clinical finding showing that CHF is
associated with marked insulin resistance, characterized
by both fasting and stimulated hyperinsulinemia. Using
laboratory experimental rat myocardial infarction, Clarke’s
group has demonstrated that insulin-stimulated D[2-3H]
glucose uptake was 42% lower in isolated perfused
infarcted hearts, was and this was accompanied by a de-
crease in expression of glucose transporter (GLUT-4), and
negatively correlated with ejection fraction and with
fasting plasma FFA concentration [21]. Notably, low
glucose uptake in chronic myocardial infarction was also
directly in line with a three-fold faster ATP hydrolysis
rate, measured using phosphorus-31 magnetic resonance
spectroscopy.
Experimental studies of GLP-1 in myocardial protection
A plethora of experimental data has been generated
concerning a role of GLP-1 in diabetes, but very limited
evidence has focused on its cardiovascular effect. Both
GLP-1(7-36) amide and the GLP-1 receptor agonist,
exendin-4 are shown to increase heart rate and blood
pressure in both anesthetized and conscious restrained
rats, although the mechanisms are controversial [22,23].
In vitro studies have failed to show any effects of GLP-1
on cardiac myocyte contractility. Very recently, promis-
ing clinical data from Shannon’s lab showed that GLP-1
infusion improved regional and global function in pa-
tients with acute myocardial ischemia and severe systolic
dysfunction after successful primary angioplasty [24].
Furthermore, in pacing-induced heart failure model, the
stimulation of GLP signaling with GLP-1 has also been
demonstrated to improve cardiac performance in conscious
dogs with dilated cardiomyopathy [25]. Infusion of GLP-1
was associated with a marked improvement in LV systolic
function and diastolic function in decompensated heart
failure. By using established isovolumetric isolated perfused
rat hearts, we observed that activation of GLP-1 receptor
with GLP-1 significantly mitigated myocardial injury as in-
dicated by an improvement in recovery of developed pres-
sure and end-diastolic pressure as well as rate pressure
products [26]. Moreover, post-ischemic myocardial im-
provement was accompanied by a significant reduction in
myocardial necrosis. GLP-1 caused an increase in myocar-
dial glucose uptake in isolated hearts, which was in agree-
ment with a previous study in which the GLP-1 promoted
myocardial glucose uptake in conscious dogs with pacing
induced dilated cardiomyopathy [25]. This may reflect a
fact that the protective effect of GLP-1 on ischemic heart
was attributed to overcoming insulin resistance under is-
chemic conditions. In agreement with our studies, evidence
from Yellon’s observations suggests that GLP-1 added
before ischemia induced a significant reduction of infarct
size as compared to the control group. However, thisprotection was abrogated by administration of GLP-1 an-
tagonist exendin (9-39) and inhibition of PI3 kinase [27].
However, Kavianpour et al. reported that GLP-1 (7-36) was
not found to alter myocardial glucose utilization;
hemodynamic variables and consequent infarction changed
in porcin myocardium despite GLP-1 increased insulin se-
cretion and decreased blood uptake [28]. The discrepancies
of GLP-1 in these studies definitely depend on the model
(in vivo/in vitro), species, and the duration of GLP-1
(short/sustained half life). Native GLP-1 is rapidly degraded
by dipeptidyl peptidase-IV (DPP-IV) in the blood stream.
Accordingly, the direct cardiovascular response of GLP-1
may be masked by the effective fragments under in vivo
conditions [29].
Clinical studies of GLP-1 in patients
The promising data obtained in experimental studies
suggest that the therapeutic strategies based on incretins
may preserve cardiomyocyte viability, increase metabolic
efficiency, and inhibit the structural and functional re-
modeling that occurs in the ischemic and the failing
heart. Against the backdrop of an expansive body of evi-
dence indicating salutary cardiovascular effects of GLP-1
in the experimental animal model, there have been sev-
eral phase 2 trials of GLP-1 in humans with cardiovascular
diseases [5,24,30]. Shannon’s group is the first to demon-
strate that infusion of GLP-1(7-36) (1.5 pmol/kg/min) for
72 hr in patients with left ventricular dysfunction after MI
improved global and regional left ventricular wall motion
scores and reduced hospital stay and in-hospital mortality.
These effects remain detectable even several weeks after
hospital discharge [5]. The benefits of GLP-1 on LVEF
were evident in both diabetic and non-diabetic patients, as
well as in patients with anterior (left anterior descending
artery) and non-anterior AMI. Sokos et al. reported that a
long-term infusion of GLP-1 improves both LVEF and
functional capacity in human patients with advanced heart
failure [30]. In a single-center pilot study, 20 obese pa-
tients with LVEF≤40% and NYHA class III or IV heart fail-
ure were divided to receive a continuous subcutaneous
infusion of GLP-1 or a small volume of saline as a control
over 5 weeks. All patients in the study were on a standard,
stable heart failure medication regimen. The group treated
with GLP-1 had significantly improved LVEF, maximum
myocardial ventilation oxygen consumption, 6-minute
walk distance and Minnesota Living with Heart failure
Quality of Life scores. GLP-1 also led to improved gly-
cemic control with an increase in plasma insulin and de-
crease in plasma NEFA levels. The promising results from
the above clinical studies were further corroborated
with additional recent data obtained in a pilot study
performed in 20 patients after percutaneous coronary
intervention confirming the cardioprotective effects of
GLP-1, ameliorating left ventricular dysfunction after
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that treatment with GLP-1 (7-36) (1.2 pmol/kg/min)
improved left ventricular function in response to stress
in 14 patients with coronary artery disease (CAD) [32].
This observation was furthered supported with an addi-
tional report that 172 patients treated with exenatide
(0.12 μg/min) for 6 hr after ST-Segment elevation MI
exhibited a significant increase in myocardial salvage
when compared with the placebo group.
Anti-hypertensive effect of GLP-1
The cardioprotective effects of GLP-1 have also been
reported in the in vivo hypertension animal models in
which GLP-1 significantly improved the survival rates of
the Spontaneously Hypertensive, Heart Failure–prone
(SHHF) rats that demonstrated preserved LV function
and LV mass index [33]. Such anti-hypertentive action
has been demonstrated in Dahl salt-sensitive (DSS) rats
in which continuous administration of recombinant
GLP-1 attenuated the development of hypertension [34].
The prevention of hypertension by GLP-1 was directly
linked to decreased LV hypotrophy in DSS as well as
higher levels of urine flow and sodium excretion, con-
tributing to the comprehensive anti-hypertension effects
of GLP-1. Liu Q et al. reported that treatment of
AC3174, an exenatide-related GLP-1R agonist, antago-
nized the hypertensive effect and prevented the develop-
ment of cardiac hypertrophy in DSS model [35]. These
data were further confirmed by the observations that in-
hibition of DPP-4 through the administration of
Sitagliptin to increase the level of biologically active in-
tact GLP-1 significantly attenuated high blood pressure
in young pre-hypertensive spontaneously hypertensive
rats (SHRs) [36]. Additionally, function and expression
of Na/H exchanger isoform 3 (NHE3) decreased but
there was increased urine flow and sodium excretion in
the tested young SHRs. Pooled data from six trials showed
that 6 months of exenatide treatment significantly reduced
systolic blood pressure in patients with type 2 diabetes
[37]. Liraglutide was evaluated in a series of phase 3 trials
and it demonstrated a promising anti-systolic blood pres-
sure effect in combination with other anti-diabetes drugs
like metformin [38]. Using transgenic mouse model, it has
recently been demonstrated that that cardiac GLP-1R acti-
vation promotes the secretion of atrial natriuretic peptide
(ANP) and a reduction of blood pressure. LGLP-1R agon-
ist liraglutide did not result in ANP secretion, vasorelax-
ation, or lower blood pressure in Glp1rdeficient mice,
revealing a gut-heart GLP-1R-dependent and ANP-
dependent axis that regulates blood pressure [39].
GLP-1 and anti-obese effects
The last few decades have witnessed a global rise in
adult obesity of epidemic proportions. The potentialimpact of this is emphasized when one considers that
body mass index (BMI) is a powerful predictor of death,
type 2 diabetes (T2DM), and cardiovascular morbidity
and mortality [40]. Weight gain and obesity are associ-
ated with structural and functional changes of the car-
diovascular system including left atrial and ventricular
remodeling, hemodynamic alterations, autonomic dys-
function, and diastolic dysfunction. Moreover, diabetic
cardiomyopathy is characterized by an adverse structural
and functional cardiac phenotype [41]. For persons with
diabetes or obesity, the chief goal is to avoid the com-
mon cardiovascular sequelae. In past years, numerous
drugs have been approved for treatment of obesity.
However, most of them are withdrawn from the market
because of their adverse effects. Li C et al. observed that
Addition of liraglutide to abdominally obese, insulin-
treated patients led to improvement in glycemic control
similar to that achieved by increasing insulin dosage
[42]. Adding liraglutide to insulin also induced a signifi-
cant reduction in body weight and waist circumference,
suggesting that Liraglutide may be the best treatment
option for poorly controlled type 2 Diabetes and abdom-
inal obesity. In agreement with this evidence, Fujishima
et al., demonstrated that Liraglutide improved visceral
fat adiposity, produced meaningful weight loss, and sig-
nificantly improved eating behavior in obese Japanese
patients with type 2 diabetes. The effect of GLP-1 recep-
tor agonist treatment on endothelial function has not
been well-described in humans [43,44]. Kelly et al. dem-
onstrated that three months of therapy through GLP-1
agonists (exenatide vs metformin) exerted similar effects
on microvascular endothelial function, inflammation,
oxidative stress, and vascular activation in patients with
obesity and pre-diabetes [45].
Signaling pathway involved by GLP-1 in myocardial
protection
We observed abundant expression of GLP-1 receptors in
the rat myocardium. However, the mechanisms whereby
GLP-1 receptors couple to intracellular effectors in
extrapancretic tissues, such as the heart, remain largely
unexplored. In turn, we observed that GLP-1 and insulin
had comparable effects on myocardial glucose uptake,
but via different cellular mechanisms. We have found
that p38 mitogen-activated protein kinase serves as an
important mechanism through which GLP-1 modulates
myocardial injury. In addition, the co-ordination be-
tween PI3K and nitric oxides in modulating cardiac
function has recently been established.
The mitogen-activated protein kinases (MAPKs)
MAPKs play a central role in the transmission of signals
from cell surface receptors and various environmental
cues to the transcriptional machinery in the nucleus
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ation [46,47]. Several distinct MAPK subfamilies have
been characterized in cardiac tissue, including the p38
MAP kinase, the stressed-activated protein kinase/c-Jun
N-terminal kinase (JUN kinase), the extracellular-
responsive kinase (ERKS), big MAPK-1(ERK5) [48]. p38
can be activated by various stresses including cytokines
and I/R [49]. p38 has been shown to be protective in
several models [50]. The p38 family of mitogen-activated
protein kinases has been shown to play an important
role in mediating stress-induced signaling in mammalian
cells. There are two predominant isoforms of p38 in
heart, α and β. Overexpression of p38 β has been shown
to induce hypertrophic responses and to promote sur-
vival of myocytes, whereas activation of p38 α antago-
nizes these effects and leads to cell death [51].
Our previous studies showed that activation of p38
protected the heart against I/R injury [52]. In line with
our observation, activation of p38 with preconditioning
stimuli or over-expression of MKK3/MKK6 has been
reported to protect the heart against myocardial I/R in-
jury [53-58]. Mutation of p38 β isoform also resulted in
increased myocardial injury [59]. However, during lethal
ischemia, ischemia and reperfusion as well as post-
conditioning p38 inhibition has been shown to result in
protection [60,61]. Transgenic mice expressing a cardiac
dominant-negative (Dn) p38 α antagonized cardiac I/R
injury, and disruption of a single copy of p38 α in mice
was reported to be less susceptible to myocardial I/R in-
jury [62,63]. Dominant negative over-expression of p38
α transgenic mice show enhanced cardiac hypertrophy
following aortic banding [64]. Dn-p38α mice had a
markedly reduced infarct size and increased ventricular
systolic function flowing chronic infarction [65]. These
conflicts remain unclear. These discrepancies may be
explained by strength of p38 activation and activation ofFigure 1 Proposed signaling pathways induced by GLP-1. GLP-1: glucago
p38 mitogen-activated protein kinase; PI3K: phosphatidylinositide 3-kinase; ERdifferent isoforms, vastly different stress conditions, and
animal species [66-68]. During low flow ischemia, we
documented that both GLP-1 and insulin-mediated glu-
cose uptake did not involve Akt-1 activation in the post-
ischemic myocardium [26]. It is intriguing to reveal from
our recent observation that GLP-1 was associated with
increased p38 activities. However, based on our current
studies, it remains unknown if these unique signaling
components are only epiphenomenon or crucial for
GLP-1 to play a protective effect. If so, what p38 iso-
form/nitric oxide synthase would be dominant in regula-
tion of cardioprotection afforded by GLP-1.
PI3K and nitric oxides
The importance of p38/nitric oxide has been addressed
based on our recent findings [52]. Inhibitors of PI3K and
p42/44 mitogen-activated protein kinase (LY294002 and
UO126), respectively as well as of p70S6K rapamycin
abolished the GLP-1-induced infarct size limitation in
rat hearts, suggesting that PI3K and p42/44 are involved
in the myocardial protection elicited by GLP-1 [27,69].
These results indicate GLP-mediated activation of reper-
fusion injury salvages kinase pathway, reminiscent of
the GLP-1 coupling to PI3K-akt-signlaing in insulin-
producing cells [70]. In addition, insulin mediated glu-
cose uptake was associated with Akt-1 phosphorylation
and GLUT 4 translocation [26]. In contrast, GLP-1 did
not increase Akt-1 phosphorylation and GLUT 4 trans-
location, but did result in increased GLUT 1 expression in
the sarcolemma. Administration of L-NG-Nitroarginine
Methyl Ester (L-NAME) attenuated this protective effect
in mouse model [71], pointing to GLP-1-mediated
cardioprotection through modulation of nitric oxides.
Some studies also reveal that GLP-1 has a dose-dependent
vasorelaxant effect, which is mediated by both endothe-
lium and nitric oxide [71,72]. Golpon et al. showed thatn-like peptide-1; GLP-1R: glucagon-like peptide-1 receptor; p38 MAPK:
: endoplasmic reticulum.
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thelial NOS (eNOS) abolished GLP-1 mediated vasorelax-
ation of rat pulmonary arteries [72]. In addition, other
studies suggested that the vasorelaxant effects of GLP-1
were mediated by activation of AMP or KATP channels
independently of nitric oxide and the endothelium [73,74].
GLP-1-activated pathway uses cyclic adenosine mono-
phosphate (cAMP) in insulin producing cells [70], and a
cAMP-dependent pathway would be essential for the
pro-survival action of GLP-1 in the heart [27]. GLP-1-
mediated stimulation of cAMP in cardiac myocytes has
been demonstrated [13].
Other signaling pathways
The endoplasmic reticulum (ER) is a multifunctional or-
ganelle responsible for the synthesis and folding of
proteins as well as calcium storage and signaling. Per-
turbations of ER function cause ER stress leading to
the unfolded protein response, which includes inhib-
ition of protein synthesis, protein refolding, and clear-
ance of misfolded proteins [75]. Growing evidence
links the ER to pathologies such as diabetes mellitus,
obesity, liver, heart, renal and neurodegenerative dis-
eases, endothelial dysfunction, atherosclerosis, and
cancer [76]. Recent discoveries regarding the role of
inflammation, mitochondrial dysfunction, and ER
stress in obesity have advanced our understanding of
how insulin resistance develops in peripheral organs
[77]. A recent observation using a diabetic cardiomy-
opathy rat model reveals that the GLP-1 analog
liraglutide improved cardiac function, which is accom-
panied with a decrease in activating transcription factor
4 (ATF4) and TNF receptor associated factor 2 (TRAF2)
and the down-regulation of Grp78 and caspase-3. This
suggests that GLP-1-induced cardioprotection may be
related to the inactivation of the ER stress signaling
pathway [78].
Conclusion
GLP-1 recently attracted attention as a therapeutic strat-
egy for diabetes, heart diseases, and obesity. Metabolic
modulation of post-ischemic myocardium and advanced
left ventricular dysfunction is an important and emer-
ging area of therapeutic investigation. Conventional ap-
proaches using insulin have been proven ineffective,
development of new strategies to promote glucose up-
take is a promising initiative. We and others have
established the significance of GLP-1 in protect the heart
against acute myocardial ischemic injury. Recently, a sig-
nificant number of studies have indicated beneficial ef-
fects of GLP-1 on cardiovascular function, which
appears to justify the usage of GLP-1 in the treatment of
cardiovascular diseases. Exploration of its downstream
signaling pathway using integrative molecular andcellular approaches and evaluation of its clinical out-
come will provide direct evidence to support potential
clinical implication (summarized in Figure 1).
Competing interests
The author declares that he has no competing interest.
Acknowledgments
The work is supported by the National Heart, Lung, and Blood Institute Grant
(R01 HL089405) and American Heart Association-National center (0735458 N)
to TCZ.
Received: 19 April 2013 Accepted: 5 June 2013
Published: 18 June 2013
References
1. Phillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany J: Cocaine
cardiotoxicity: a review of the pathophysiology, pathology, and
treatment options. Am J Cardiovasc Drugs 2009, 9(3):177–196.
2. Eltzschig HK, Eckle T: Ischemia and reperfusion-from mechanism to
translation. Nat Med 2011, 17(11):1391–1401.
3. Kostis JB, Sanders M: The association of heart failure with insulin
resistance and the development of type 2 diabetes. Am J Hypertens 2005,
18(5 Pt 1):731–737.
4. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC,
Coats AJJ: Insulin resistance in chronic heart failure: relation to severity
and etiology of heart failure. Am Coll Cardiol 1997, 30(2):527–532.
5. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP:
Effects of glucagon-like peptide-1 in patients with acute myocardial
infarction and left ventricular dysfunction after successful reperfusion.
Circulation 2004, 109(8):962–965.
6. Drucker DJ: Glucagon-like peptides: regulators of cell proliferation,
differentiation, and apoptosis. Mol Endocrinol 2003, 17(2):161–171.
7. Drucker DJ: Biological actions and therapeutic potential of the glucagon-
like peptides. Gastroenterology 2002, 122(2):531–544.
8. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang
Q, Drucker DJ, Husain M: Cardiac function in mice lacking the glucagon-
like peptide-1 receptor. Endocrinology 2003, 144(6):2242–2252.
9. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M: Protein
kinase Czeta activation mediates glucagon-like peptide-1-induced
pancreatic beta-cell proliferation. Diabetes 2001, 50(10):2237–2243.
10. Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS,
Nielsen JH, Møldrup A: Stimulation of pancreatic beta-cell replication by
incretins involves transcriptional induction of cyclin D1 via multiple
signalling pathways. J Endocrinol 2006, 188(3):481–492.
11. Stoffers DA, Desai BM, DeLeon DD, Simmons RA: Neonatal exendin-4
prevents the development of diabetes in the intrauterine growth
retarded rat. Diabetes 2003, 52(3):734–740.
12. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger
ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.
Endocrinology 1996, 137(7):2968–2978.
13. Vila Petroff MG, Egan JM, Wang X, Sollott SJ: Glucagon-like peptide-1
increases cAMP but fails to augment contraction in adult rat cardiac
myocytes. Circ Res 2001, 89(5):445–452.
14. Wei Y, Mojsov S: Tissue-specific expression of the human receptor for
glucagon-like peptide-I: brain, heart and pancreatic forms have the
same deduced amino acid sequences. FEBS Lett 1995, 358(3):219–224.
15. Brubaker PL, Drucker DJ: Glucagon-like peptides regulate cell proliferation
and apoptosis in the pancreas, gut, and central nervous system.
Endocrinology 2004, 145(6):2653–2659.
16. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988,
37:1595–1607.
17. Opie LH: The heart, physiology and metabolism. New York: Raven; 1991.
18. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial
ischaemia and arrhythmias. Lancet 1994, 343:155–158.
19. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC,
Coats AJ: Insulin resistance in chronic heart failure: relation to severity
and etiology of heart failure. J Am Coll Cardiol 1997, 30(2):527–532.
20. Levantesi G, Macchia A, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL,
Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R, on behalf of the
GISSI-Prevenzione Investigators: Metabolic syndrome and risk of
Zhao Cardiovascular Diabetology 2013, 12:90 Page 7 of 8
http://www.cardiab.com/content/12/1/90cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005,
46:277–283.
21. Paternostro G, Clarke K, Heath J, Seymour AM, Radda GK: Decreased GLUT-4
mRNA content and insulin-sensitive deoxyglucose uptake show insulin
resistance in the hypertensive rat heart. Cardiovasc Res 1995, 30(2):205–211.
22. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME,
Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK: Glucagon-like
peptide-1 receptor stimulation increases blood pressure and heart rate
and activates autonomic regulatory neurons. J Clin Invest 2002,
110(1):43–52.
23. Barragán JM, Rodríguez RE, Eng J, Blázquez E: Interactions of exendin-[9-39]
with the effects of glucagon-like peptide-1-[7-36] amide and of exendin-4
on arterial blood pressure and heart rate in rats. Regul Pept 1996,
67(1):63–68.
24. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD,
Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP: Effect of
glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular
function in patients undergoing coronary artery bypass grafting. Am J
Cardiol 2007, 100(5):824–829.
25. Nikolaidis L, Elahi D, Shen Y, Shannon RP: Active metabolite of GLP-1
mediates myocardial glucose uptake and improves ventricular
performance in conscious dogs with dilated cardiomyopathy. Am J
Physiol Heart Circ Physiol 2005, 289(6):H2401–H2408.
26. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon
RP: Direct effects of glucagon-like peptide-1 on myocardial contractility
and glucose uptake in normal and postischemic isolated rat hearts.
J Pharmacol Exp Ther 2006, 317(3):1106–1113.
27. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like
peptide 1 can directly protect the heart against ischemia/reperfusion
injury. Diabetes 2005, 54(1):146–151.
28. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G,
Gutniak M: Glucagon-like peptide-1 (7–36) amide prevents the
accumulation of pyruvate and lactate in the ischemic and non-ischemic
porcine myocardium. Peptides 2003, 24:569–578.
29. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses
gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide,
peptide histidine methionine and is responsible for their degradation in
human serum. Eur J Biochem 1993, 214:829–835.
30. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP: Glucagon-like
peptide-1 infusion improves left ventricular ejection fraction and
functional status in patients with chronic heart failure. J Card Fail 2006,
12(9):694–699.
31. Read PA, Hoole SP, White PA, Khan FZ, O’Sullivan M, West NE, Dutka DP: A
pilot study to assess whether glucagon-like peptide-1 protects the heart
from ischemic dysfunction and attenuates stunning after coronary
balloon occlusion in humans. Circ Cardiovasc Interv 2011, 4(3):266–272.
32. Read PA, Khan FZ, Dutka DP: Cardioprotection against ischaemia induced
by dobutamine stress using glucagon-like peptide-1 in patients with
coronary artery disease. Heart 2012, 98(5):408–413.
33. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP:
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic
function and prolongs survival in the spontaneously hypertensive, heart
failure-prone rat. Circ Heart Fail 2008, 1(3):153–160.
34. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ:
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive
rats. J Hypertens 2003, 6:1125–1135.
35. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG: The
exenatide analogue AC3174 attenuates hypertension, insulin resistance,
and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010,
9(1):32.
36. Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, Girardi
AC: Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in
young spontaneously hypertensive rats. J Hypertens 2011, 29(3):520–528.
37. Okerson T, Yan P, Stonehouse A, Brodows R: Effects of exenatide on
systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens
2010, 23(3):334–339.
38. Blonde L, Russell-Jones D: The safety and efficacy of liraglutide with or
without oral antidiabetic drug therapy in type 2 diabetes: an overview
of the LEAD 1–5 studies. Diabet Obes Metab 2009, 11(suppl3):26–34.
39. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA,
Drucker DJ: GLP-1 receptor activation and Epac2 link atrial natriureticpeptide secretion to control of blood pressure. Nature Med 2013,
19(5):567–575.
40. Bender SB, McGraw AP, Jaffe IZ, Sowers JR: Mineralocorticoid receptor-
mediated vascular insulin resistance: an early contributor to diabetes-
related vascular disease? Diabetes 2013, 62(2):313–319.
41. Asghar O, Alam U, Hayat SA, Aghamohammadzadeh R, Heagerty AM, Malik
RA: Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms
and interventions. Curr Cardiol Rev 2012, 8(4):253–264.
42. Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM: Efficacy and safety
comparison between liraglutide as add-on therapy to insulin and insulin
dose-increase in Chinese subjects with poorly controlled type 2 diabetes
and abdominal obesity. Cardiovasc Diabetol 2012, 11:142.
43. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J,
Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I: Efficacy of
liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight,
eating behavior, and glycemic control, in Japanese obese type 2
diabetes. Cardiovasc Diabetol 2012, 11:107.
44. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita
K, Imagawa A, Funahashi T, Shimomura I: Short-term effects of liraglutide
on visceral fat adiposity, appetite, and food preference: a pilot study of
obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 2011,
10:109.
45. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ: Effects of
exenatide vs. metformin on endothelial function in obese patients with
pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64.
46. Cobb M, Goldsmith EJ: How MAP kinases are regulated. J Biol Chem 1995,
270:14843–14846.
47. Hill CS, Treisman R: Transcriptional regulation by extracellular signals:
mechanisms and specificity. Cell 1995, 80:199–211.
48. Rose BA, Force T, Wang Y: Mitogen-activated protein kinase signaling in
the heart: angels versus demons in a heart-breaking tale. Physiol Rev
2010, 90(4):1507–1546.
49. Nishida E, Gotoh Y: The MAP kinase cascade is essential for diverse signal
transduction pathways. Trends Biochem Sci 1993, 18:128–131.
50. Zhao TC, Hines DS, Kukreja RC: Adenosine-induced late preconditioning in
mouse hearts: role of p38 MAP kinase and mitochondrial KATP channels.
Am J Physiol Heart Circ Physiol 2001, 280:H1278–H1285.
51. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR: Cardiac
muscle cell hypertrophy and apoptosis induced by distinct members of
the p38 mitogen-activated protein kinase family. J Biol Chem 1998,
273(4):2161–2168.
52. Zhao TC, Taher MM, Valerie KC, Kukreja RC: p38 Triggers late
preconditioning elicited by anisomycin in heart: involvement of
NF-kappaB and iNOS. Circ Res 2001, 89:915–922.
53. Martindale JJ, Wall JA, Martinez-Longoria DM, Aryal P, Rockman HA, Guo Y,
Bolli R, Glembotski CC: Overexpression of mitogen-activated protein
kinase kinase 6 in the heart improves functional recovery from ischemia
in vitro and protects against myocardial infarction in vivo. J Biol Chem
2005, 280:669–676.
54. Peart JN, Gross ER, Headrick JP, Gross GJ: Impaired p38 MAPK/HSP27
signaling underlies aging-related failure in opioid-mediated
cardioprotection. J Mol Cell Cardiol 2007, 42:972–980.
55. Dana A, Skarli M, Papakrivopoulou J, Yellon DM: Adenosine A(1) receptor
induced delayed preconditioning in rabbits: induction of p38 mitogen-
activated protein kinase activation and Hsp27 phosphorylation via a
tyrosine kinase- and protein kinase C-dependent mechanism. Circ Res
2000, 86:989–997.
56. Schulz R, Belosjorow S, Gres P, Jansen J, Michel MC, Heusch G: p38 MAP
kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res
2002, 55:690–700.
57. Haq SE, Clerk A, Sugden PH: Activation of mitogen-activated protein
kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the
perfused rat heart. FEBS Lett 1998, 434:305–308.
58. Kabir AM, Cao X, Gorog DA, Tanno M, Bassi R, Bellahcene M, Quinlan RA,
Davis RJ, Flavell RA, Shattock MJ, Marber MS: Antimycin A induced
cardioprotection is dependent on pre-ischemic p38-MAPK activation but
independent of MKK3. J Mol Cell Cardiol 2005, 39:709–717.
59. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS: Antiischemic effects
of SB203580 are mediated through the inhibition of p38alpha mitogen-
activated protein kinase: Evidence from ectopic expression of an
inhibition-resistant kinase. Circ Res 2001, 89:750–752.
Zhao Cardiovascular Diabetology 2013, 12:90 Page 8 of 8
http://www.cardiab.com/content/12/1/9060. Sun HY, Wang NP, Halkos M, Kerendi F, Kin H, Guyton RA, Vinten-Johansen
J, Zhao ZQ: Postconditioning attenuates cardiomyocyte apoptosis via
inhibition of JNK and p38 mitogen-activated protein kinase signaling
pathways. Apoptosis 2006, 11:1583–1593.
61. Ma XL, Kumar S, Louden CS, Lopez BL, Christoper TA, Wang C, Lee JC,
Feuerstein GZ, Yue TL: Inhibition of p38 mitogen-activated protein kinase
decrease cardiomyocyte apoptosis and improves cardiac function after
myocardial ischemia and reperfusion. Circulation 1999, 99:1685–1691.
62. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF,
Molkentin JD: Targeted inhibition of p38 mitogen-activated protein
kinase antagonizes cardiac injury and cell death following ischemia-
reperfusion in vivo. J Biol Chem 2004, 279:15524–15530.
63. Otsu K, Yamashita N, Nishida K, Hirotani S, Yamaguchi O, Watanabe T,
Hikoso S, Higuchi Y, Matsumura Y, Maruyama M, Sudo T, Osada H, Hori M:
Disruption of a single copy of the p38alpha MAP kinase gene leads to
cardioprotection against ischemia-reperfusion. Biochem Biophys Res
Commun 2003, 302:56–60.
64. Liu J, Sadoshima J, Zhai P, Hong C, Yang G, Chen W, Yan L, Wang Y, Vatner
SF, Vatner DE: Pressure overload induces greater hypertrophy and
mortality in female mice with p38alpha MAPK inhibition. J Mol Cell
Cardiol 2006, 41(4):680–688.
65. Muslin AJ: MAPK signalling in cardiovascular health and disease:
molecular mechanisms and therapeutic targets. Clin Sci (Lond) 2008,
115(7):203–218.
66. Ping P, Murphy E: Role of p38 mitogen-activated protein kinases in
preconditioning: a detrimental factor or a protective kinase? Circ Res
2000, 86:921–922.
67. Steenbergen C: The role of p38 mitogen-activated protein kinase in
myocardial ischemia/reperfusion injury; relationship to ischemic
preconditioning. Basic Res Cardiol 2002, 97:276–285.
68. Sugden PH, Clerk A: “Stress-responsive” mitogen-activated protein
kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein
kinases) in the myocardium. Circ Res 1998, 83:345–352.
69. Bose AK, Mocanu MM, Carr RD, Yellon DM: Myocardial ischaemia-
reperfusion injury is attenuated by intact glucagon like peptide-1
(GLP-1) in the in vitro rat heart and may involve the p70s6K pathway.
Cardiovasc Drugs Ther 2007, 21(4):253–256.
70. Doyle ME, Egan JM: Mechanisms of action of glucagon-like peptide 1 in
the pancreas. Pharmacol Ther 2007, 113(3):546–593.
71. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M:
Cardioprotective and vasodilatory actions of glucagon-like peptide 1
receptor are mediated through both glucagon-like peptide 1 receptor-
dependent and -independent pathways. Circulation 2008, 117(18):2340–2350.
72. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO: Vasorelaxant
effect of glucagon-like peptide-(7–36)amide and amylin on the
pulmonary circulation of the rat. Regul Pept 2001, 102(2–3):81–86.
73. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ:
GLP-1 and related peptides cause concentration-dependent relaxation
of rat aorta through a pathway involving KATP and cAMP. Arch Biochem
Biophys 2008, 478(2):136–142.
74. Nyström T, Gonon AT, Sjöholm A, Pernow J: Glucagon-like peptide-1
relaxes rat conduit arteries via an endothelium-independent mechanism.
Regul Pept 2005, 125(1–3):173–177.
75. Toth A, Nickson P, Mandl A, Bannister ML, Toth K, Erhardt P: Endoplasmic
reticulum stress as a novel therapeutic target in heart diseases.
Cardiovasc Hematol Disord Drug Targets 2007, 7(3):205–218.
76. Popov D: Endoplasmic reticulum stress and the on site function of
resident PTP1B. Biochem Biophys Res Commun 2012, 422(4):535–538.
77. Gray S, Kim JK: New insights into insulin resistance in the diabetic heart.
Trends Endocrinol Metab 2011, 22(10):394–403.
78. Liu J, Liu Y, Chen L, Wang Y, Li J: Glucagon-Like peptide-1 analog
liraglutide protects against diabetic cardiomyopathy by the inhibition of
the endoplasmic reticulum stress pathway. J Diabetes Res 2013,
2013:630537.
doi:10.1186/1475-2840-12-90
Cite this article as: Zhao: Glucagon-like peptide-1 (GLP-1) and
protective effects in cardiovascular disease: a new therapeutic approach
for myocardial protection. Cardiovascular Diabetology 2013 12:90.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
